Brokerages forecast that Diplomat Pharmacy Inc (NYSE:DPLO) will post earnings of $0.23 per share for the current fiscal quarter, according to Zacks Investment Research. Seven analysts have issued estimates for Diplomat Pharmacy’s earnings, with the lowest EPS estimate coming in at $0.19 and the highest estimate coming in at $0.38. Diplomat Pharmacy posted earnings of $0.19 per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 21.1%. The firm is scheduled to report its next earnings report on Monday, May 14th.
According to Zacks, analysts expect that Diplomat Pharmacy will report full year earnings of $0.98 per share for the current year, with EPS estimates ranging from $0.90 to $1.36. For the next year, analysts forecast that the firm will report earnings of $1.15 per share, with EPS estimates ranging from $1.01 to $1.46. Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that that provide coverage for Diplomat Pharmacy.
Diplomat Pharmacy (NYSE:DPLO) last announced its quarterly earnings data on Monday, February 26th. The company reported $0.18 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.16 by $0.02. Diplomat Pharmacy had a return on equity of 8.89% and a net margin of 0.35%. The firm had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.17 billion. During the same quarter in the prior year, the company posted $0.08 earnings per share. Diplomat Pharmacy’s quarterly revenue was up .9% on a year-over-year basis.
A number of brokerages recently weighed in on DPLO. Deutsche Bank raised Diplomat Pharmacy from a “hold” rating to a “buy” rating in a report on Friday, March 2nd. Needham & Company LLC set a $28.00 price objective on Diplomat Pharmacy and gave the stock a “buy” rating in a report on Tuesday, February 27th. Wells Fargo & Co reissued a “market perform” rating and issued a $25.00 target price (up previously from $21.50) on shares of Diplomat Pharmacy in a report on Tuesday, February 27th. Leerink Swann set a $30.00 target price on Diplomat Pharmacy and gave the company a “buy” rating in a report on Tuesday, February 27th. Finally, Zacks Investment Research lowered Diplomat Pharmacy from a “buy” rating to a “hold” rating in a report on Wednesday, February 21st. Eight research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Diplomat Pharmacy presently has an average rating of “Hold” and a consensus target price of $24.79.
Shares of Diplomat Pharmacy (NYSE:DPLO) traded down $0.33 during mid-day trading on Wednesday, reaching $21.03. The company had a trading volume of 677,719 shares, compared to its average volume of 936,358. Diplomat Pharmacy has a 52-week low of $14.00 and a 52-week high of $27.78. The firm has a market capitalization of $1,450.00, a price-to-earnings ratio of 61.85 and a beta of 1.32. The company has a debt-to-equity ratio of 0.70, a current ratio of 0.97 and a quick ratio of 0.66.
Institutional investors have recently bought and sold shares of the business. Chicago Equity Partners LLC acquired a new stake in Diplomat Pharmacy in the fourth quarter valued at $1,215,000. Jennison Associates LLC acquired a new stake in shares of Diplomat Pharmacy during the fourth quarter valued at $308,000. Strs Ohio acquired a new stake in shares of Diplomat Pharmacy during the fourth quarter valued at $800,000. Wrapmanager Inc. boosted its stake in shares of Diplomat Pharmacy by 14.4% during the fourth quarter. Wrapmanager Inc. now owns 16,212 shares of the company’s stock valued at $325,000 after acquiring an additional 2,044 shares during the last quarter. Finally, Royal Bank of Canada boosted its stake in shares of Diplomat Pharmacy by 25.0% during the second quarter. Royal Bank of Canada now owns 35,266 shares of the company’s stock valued at $521,000 after acquiring an additional 7,056 shares during the last quarter. 64.52% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: “Zacks: Analysts Anticipate Diplomat Pharmacy Inc (DPLO) Will Post Earnings of $0.23 Per Share” was first published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this piece on another site, it was illegally copied and republished in violation of international copyright and trademark laws. The correct version of this piece can be read at https://www.thelincolnianonline.com/2018/03/14/zacks-analysts-anticipate-diplomat-pharmacy-inc-dplo-will-post-earnings-of-0-23-per-share.html.
Diplomat Pharmacy Company Profile
Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.